A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Management and outcome of salivary duct carcinoma in major salivary glands




TekijätSalovaara E, Hakala O, Back L, Koivunen P, Saarilahti K, Passador-Santos F, Leivo I, Makitie AA

KustantajaSPRINGER

Julkaisuvuosi2013

JournalEuropean Archives of Oto-Rhino-Laryngology

Tietokannassa oleva lehden nimiEUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY

Lehden akronyymiEUR ARCH OTO-RHINO-L

Numero sarjassa1

Vuosikerta270

Numero1

Aloitussivu281

Lopetussivu285

Sivujen määrä5

ISSN0937-4477

DOIhttps://doi.org/10.1007/s00405-012-1997-4


Tiivistelmä
Salivary duct carcinoma (SDC) is a rare and aggressive malignancy with poor prognosis. Its histomorphology is distinctly reminiscent of the ductal carcinoma of the breast. We reviewed the treatment and outcome of SDCs at a single tertiary care centre. Twenty-five cases of SDC of major salivary gland origin, diagnosed and treated at the Department of Otolaryngology, Head and Neck Surgery, Helsinki University Central Hospital, Helsinki, Finland, during a 14-year period from 1997 to 2011, were reviewed retrospectively. Survival outcome was analyzed for 18 patients with a minimum follow-up of 24 months. There were 16 male (64 %) and 9 female (36 %) patients with a median age of 61 years (range 36-82 years). The majority of the cases occurred in the parotid gland (n = 21, 84 %) followed by the submandibular gland (n = 4, 16 %). The primary treatment consisted of surgical resection in all cases and 17 (68 %) patients also underwent neck dissection. Most of the patients (n = 18, 72 %) were treated with postoperative radiotherapy. Seven patients (28 %) had a disease recurrence within a median follow-up time of 15 months (range 3-27 months). In the group (n = 18) with a minimum follow-up time of 24 months, the 2- and 5-year overall and disease-specific survival rates were 66, 41 % and 75, 55 %, respectively. These results confirm the aggressive nature of SDCs in major salivary glands. Diagnostics and management of these tumours need to be centralized in experienced surgical Head and Neck Oncology Centres, and new treatment strategies should be investigated.



Last updated on 2024-26-11 at 11:58